98%
921
2 minutes
20
Objective: To develop a risk score model based on drug-sensitivity-related genes to predict the prognosis of patients with oral squamous cell carcinoma (OSCC).
Methods And Materials: In this study, transcriptome from OSCC patients was downloaded from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases, and differential gene expression analysis was performed using R's 'limma' package. LASSO Cox regression identified key prognostic genes. We stratified patients into low- and high-risk groups and estimated survival rates using Kaplan-Meier. Gene set enrichment analysis (GSEA) and immune infiltration analysis were conducted to understand the potential pathways and tumour microenvironment. A nomogram model was constructed for prognosis prediction.
Results: Our study identified 118 candidate genes from three data sets and narrowed them down to four prognostic genes (IGF2BP2, PLAU, CEP55, CMYA5) using univariate Cox regression and LASSO Cox regression. A risk score model was developed which could predict patient prognosis. The model's prognostic value was independent of age, gender, and stage. A nomogram model incorporating risk score and age was constructed for personalised survival prediction. Tumour mutation burden analysis showed that the mutation rate of TP53 was higher in the high-risk group. Immune landscape analysis uncovered distinct immune cell infiltration patterns and immune checkpoint expression levels between different risk groups, suggesting implications for immunotherapy strategies.
Conclusion: The risk score model constructed using drug-sensitivity-related genes IGF2BP2, PLAU, CEP55, and CMYA5 may predict the prognosis of OSCC patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327071 | PMC |
http://dx.doi.org/10.3290/j.ohpd.c_2124 | DOI Listing |
Prenat Diagn
September 2025
Department of Cardiology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Objective: To evaluate a structured communication training for providers performing prenatal counseling for patients presenting to a multidisciplinary maternal fetal care center.
Method: Providers who care for pregnant patients with high-risk fetal conditions participated in two half-day virtual training sessions using the VitalTalk methodology. In each session, providers learned the methodology and then participated in role-play with standardized actors.
Cardiovasc Diabetol
September 2025
Computational Biomedicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as Empagliflozin, are antidiabetic drugs that reduce glucose levels and have emerged as a promising therapy for patients with heart failure (HF), although the exact molecular mechanisms underlying their cardioprotective effects remain to be fully elucidated. The EmDia study, a randomized, double-blind trial conducted at the University Medical Center of Mainz, has confirmed the beneficial effects of Empagliflozin in HF patients after both one and twelve weeks of treatment. In this work, we aimed to assess whether changes in lipid profiles driven by Empagliflozin use in HF patients in the EmDia trial could assist in gaining a better understanding of its cardioprotective mechanisms.
View Article and Find Full Text PDFInt J Epidemiol
August 2025
Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Background: The relationship between nutritional status and tuberculosis is critically important but poorly understood. We extended a 2009 review characterizing the relationship between body mass index (BMI) and tuberculosis risk.
Methods: We systematically searched for new studies published between 2009 and 2024 investigating BMI and tuberculosis risk in adults.
Breast Cancer Res
September 2025
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Background: Polygenic risk scores (PRS) are not yet standard in clinical risk assessments for familial breast cancer in Sweden. This study evaluated the distribution and impact of an established PRS (PRS) in women undergoing clinical sequencing for hereditary breast cancer.
Findings: We integrated PRS into a hereditary breast cancer gene panel used in clinical practice and calculated scores for 262 women.
BMC Pregnancy Childbirth
September 2025
Department of Psychology, Reykjavik University, Reykjavík, Iceland.